Retatrutide and the Grey Market: Buyer Beware
This should go without saying, but the internet can be both an incredible resource and an extremely dangerous place for health and wellness information. At a time when obesity rates are soaring, mental and emotional stress are at an all-time high, and access to reputable healthcare can feel nearly impossible, many people are turning online in search of solutions. Unfortunately, that desperation leaves individuals vulnerable to the predatory promises of the wellness industry. The latest example is the buzz around retatrutide, or “Reta,” as it’s trending on TikTok.
Like candy offered from the back of a van, it’s tempting, accessible, and depending on who you ask, may even appear harmless or beneficial.
Read on to learn more about the dangers of obtaining “Reta” from the grey market and how clinicians can help patients navigate this growing concern.
What is Retatrutide?
Considered the newest GLP-1–based therapy on the horizon, retatrutide is a triple receptor agonist that targets GLP-1, GIP, and glucagon receptors. Early clinical trials suggest it may represent a groundbreaking advancement in obesity and diabetes treatment.
However, unlike semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), retatrutide is not on the market. It remains in clinical trials and is still undergoing rigorous research and safety testing. Experts estimate its first potential FDA approval for obesity and type 2 diabetes treatment sometime in late 2026 or early 2027.
How Does Retatrutide Work in the Body?
Retatrutide works through many of the same mechanisms as semaglutide and tirzepatide, including reducing appetite, increasing fullness, and slowing gastric emptying. It also adds a third pathway by activating glucagon receptors.
Glucagon is a hormone produced by the pancreas that raises blood glucose levels by breaking down stored glycogen and promoting new glucose production in the liver. This helps prevent hypoglycemia during fasting and allows the body to tap into energy reserves when food is not available. In addition to stabilizing glucose, glucagon decreases fat storage and increases fat breakdown, which raises ketone production as part of the pathway to weight loss.
What Are the Benefits of Retatrutide?
Early clinical trial data suggest impressive benefits, with reports of up to 24% body weight loss in under a year. Here’s a summary of what current research shows so far.
Weight Loss
For individuals living with obesity, weight loss outcomes in early trials consistently exceeded expectations. Participants taking the 12 mg dose lost an average of about 24% of their body weight by week 72. The results were consistent as well, with over 58% of participants achieving at least a 20% reduction in body weight.
Diabetes Management
While individuals with preexisting diabetes were intentionally excluded from preliminary studies, secondary endpoints still showed improvements in A1c, fasting glucose, and fasting insulin, suggesting strong potential for future use in diabetes management.
Cardiovascular Health, Sleep Apnea, and More
Retatrutide is also being evaluated in the TRIUMP Trial Program for potential benefits in cardiovascular health, obstructive sleep apnea, fatty liver disease, chronic kidney disease, and even pain associated with osteoarthritis.
Is Retatrutide Safe?
In short, we don’t know yet. There isn’t enough evidence to determine whether retatrutide is safe. The medication is still in the clinical trial process and is not approved by the FDA.
Based on what we know so far, it will likely carry similar risks and side effects to medications like semaglutide and tirzepatide. These may include nausea, diarrhea, constipation, and vomiting. A small number of participants in early trials also experienced more serious effects, such as increased heart rate, elevated liver enzymes, and kidney concerns.
We should have more clarity as the TRIUMPH trial program concludes in mid-2026.
So, How Are People Getting “Reta”?
This is where things get shady, quickly. Right now, the only legitimate way to access retatrutide is through enrollment in a clinical trial. For those who don’t qualify, many are turning to online compounding pharmacies, essentially the grey market of weight-loss drugs.
This raises major concerns about safety, dosing, and quality control. There is no guarantee that these products contain what they claim. We saw the same issues with compounded semaglutide and tirzepatide. And because retatrutide is not FDA-approved, there is no standardized dosing schedule, no prescription oversight, and no medical supervision.
A quick search on social media using hashtags like #reta or #retatrutide pulls up countless posts from people touting benefits like rapid fat loss, more energy, improved mood, and better overall health. A peek into the comments often reveals “suppliers,” many of whom are operating entirely outside regulated channels.
Is Retatrutide Legal?
Ethically, if you are not enrolled in a clinical trial, you should not be buying or selling retatrutide. Legally, the situation becomes more complicated and depends largely on whether you are the one purchasing or distributing the drug.
The nuance is likely why compounding pharmacies and word-of-mouth “services” have been able to grow and thrive in the grey market.
Selling Retatrutide
Selling retatrutide is not legal. Because it is not FDA-approved, it cannot be legally manufactured, marketed, sold, or prescribed in the United States outside of a registered clinical trial.
Compounded versions are also unlawful. Without an FDA-approved retatrutide product, there is no legal source ingredient for compounding, and any pharmacy or individual offering “compounded retatrutide” is operating outside FDA regulations. Selling or distributing an unapproved drug is considered a federal violation.
Buying Retatrutide
Because retatrutide is not a “banned” substance, it is technically not classified as “illegal.” Many consumers are purchasing compounded versions labeled as “research chemicals” or “not for human consumption” to exploit a legal gray area.
While the FDA has issued multiple warnings to sellers, there is little the agency can do to regulate or monitor individual consumers. Their primary tools are education and public warnings about the dangers of purchasing counterfeit drugs.
The Bottom Line on Retatrutide
While the promise of retatrutide is generating understandable excitement, it’s essential to help patients navigate the risks.
- Retatrutide remains an experimental medication still in Phase 3 clinical trials.
- It is not FDA-approved, and there is no legal or regulated supply available for consumer use.
- Online products labeled “for research purposes only” operate entirely outside regulatory oversight, making their safety and dosing highly uncertain.
The safest and most ethical approach is to guide patients toward FDA-approved treatments and reinforce why unapproved compounds are not appropriate for clinical use.
Bring GLP-1 Expertise to Your Practice
Are you looking to build or strengthen a weight management or GLP-1 program in your practice? I offer contract and consulting services to help practices design, implement, and optimize evidence-based programs.
Whether you need help developing clinical workflows, nutrition frameworks, staff training, patient education, or ongoing quality improvement, I can partner with you to create a program that meets the needs. Reach out to discuss how we can build something meaningful for your practice and your patients.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. Published 2025 May 30. doi:10.3390/biom15060796.
- Retatrutide promises big weight loss, but safety remains a question. EverydayHealth.com. https://www.everydayhealth.com/weight-management/what-is-retatrutide/. Accessed November 30, 2025.
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes and Obesity (TRIUMPH-2). NCT05929079. https://clinicaltrials.gov/study/NCT05929079
- What retatrutide clinical trials are being conducted in people with obesity or overweight? https://medical.lilly.com/us/products/answers/what-retatrutide-clinical-trials-are-being-conducted-in-people-with-obesity-or-overweight-229656. Accessed December 2, 2025.
- Research C for DE and. Fda’s concerns with unapproved glp-1 drugs used for weight loss. FDA. September 2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed December 2, 2025.
- Turnock LA, Hearne E, Lazuras L. Made in China: The international supply of illicit Semaglutide and weight-loss medicines online. Emerging Trends in Drugs, Addictions, and Health. 2025;5:100169. doi:10.1016/j.etdah.2024.100169
Discover more from Sarah Hormachea
Subscribe to get the latest posts sent to your email.
